基础医学与临床 ›› 2017, Vol. 37 ›› Issue (2): 265-269.

• 短篇综述 • 上一篇    下一篇

mTOR抑制剂抗动脉粥样硬化的研究进展

刘丽乔1,王群2   

  1. 1. 南昌大学医学院生物化学与分子生物学教研室
    2. 南昌大学第一附属医院
  • 收稿日期:2016-03-28 修回日期:2016-05-29 出版日期:2017-02-05 发布日期:2017-01-16
  • 通讯作者: 王群 E-mail:wangqun98054@sina.com
  • 基金资助:
    移植静脉重塑中PCNA及其配体蛋白的蛋白组学研究

Research progress of mTOR inhibitors for anti-atherosclerosis

LIU Li-qiao 1,   

  • Received:2016-03-28 Revised:2016-05-29 Online:2017-02-05 Published:2017-01-16
  • Supported by:
    Proteomics Research on the function of the PCNA and itsLigadins in the vein graft remodeling

摘要: 雷帕霉素靶蛋白(mTOR)是哺乳动物细胞中的Ser/Thr激酶,存在mTORC1和mTORC2两种复合体,调控细胞增殖、迁移及血管生成。大环内酯类免疫抑制剂雷帕霉素(RAPA)及其衍生物(rapalogs)可抑制mTORC1的功能,减缓动脉粥样硬化(AS)的发生发展。然而长期应用rapalogs会导致mTORC1抵抗及mTORC2抑制,产生血脂异常等。临床上采取联合用药、间歇性给药或低剂量给药等措施应对。

关键词: 关键词 动脉粥样硬化, 雷帕霉素靶蛋白, 雷帕霉素, 雷帕霉素衍生物

Abstract: Mammalian target of rapamycin (mTOR) is a kind of Ser/Thr kinase that exists in mammalian cells can regulate cell proliferation, migration and angiogenesis. mTOR including mTORC1 and mTORC2 two different complex forms. Originally developed as an anti-fungal agent, rapamycin and rapalogs were soon found to have powerful immunosuppressant properties and thus be valuable for preventing the progress of the artery atheromatous by inhibiting the function of mTORC1. But long-term rapalogs administration may increase the side actions such as mTORC1 resistance, mTORC2 inhibition, dyslipidemia. The clinical application of drug combination and dosing interval is in order to reduce the occurrence of adverse events.

Key words: Key words: Atherosclerosis, mTOR, rapamycin, rapalogs

中图分类号: